AU2013201780B2 - Phenyl Amino Pyrimidine Bicyclic Compounds And Uses Thereof - Google Patents

Phenyl Amino Pyrimidine Bicyclic Compounds And Uses Thereof Download PDF

Info

Publication number
AU2013201780B2
AU2013201780B2 AU2013201780A AU2013201780A AU2013201780B2 AU 2013201780 B2 AU2013201780 B2 AU 2013201780B2 AU 2013201780 A AU2013201780 A AU 2013201780A AU 2013201780 A AU2013201780 A AU 2013201780A AU 2013201780 B2 AU2013201780 B2 AU 2013201780B2
Authority
AU
Australia
Prior art keywords
compound
formula
disease
mmol
oxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013201780A
Other languages
English (en)
Other versions
AU2013201780A1 (en
Inventor
Christopher John Burns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YM Biosciences Australia Pty Ltd
Original Assignee
YM Biosciences Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by YM Biosciences Australia Pty Ltd filed Critical YM Biosciences Australia Pty Ltd
Priority to PCT/AU2013/000687 priority Critical patent/WO2014000032A1/en
Priority to CA2877923A priority patent/CA2877923C/en
Priority to HK15109881.6A priority patent/HK1209120B/en
Priority to ES13809739.9T priority patent/ES2644606T3/es
Priority to EP13809739.9A priority patent/EP2867238B1/en
Priority to NZ703343A priority patent/NZ703343A/en
Priority to JP2015518724A priority patent/JP5931288B2/ja
Priority to PT138097399T priority patent/PT2867238T/pt
Priority to HK15109468.7A priority patent/HK1208861A1/xx
Priority to CN201380041191.XA priority patent/CN104583216A/zh
Publication of AU2013201780A1 publication Critical patent/AU2013201780A1/en
Application granted granted Critical
Publication of AU2013201780B2 publication Critical patent/AU2013201780B2/en
Priority to JP2015178970A priority patent/JP6153980B2/ja
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2013201780A 2012-06-29 2013-03-21 Phenyl Amino Pyrimidine Bicyclic Compounds And Uses Thereof Ceased AU2013201780B2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2015518724A JP5931288B2 (ja) 2012-06-29 2013-06-26 フェニルアミノピリミジン二環式化合物およびその使用
HK15109881.6A HK1209120B (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
ES13809739.9T ES2644606T3 (es) 2012-06-29 2013-06-26 Compuestos bicíclicos de fenil amino pirimidina y usos de los mismos
EP13809739.9A EP2867238B1 (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
NZ703343A NZ703343A (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
PT138097399T PT2867238T (pt) 2012-06-29 2013-06-26 Compostos bicíclicos de fenil amino pirimidina e utilizações dos mesmos
PCT/AU2013/000687 WO2014000032A1 (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
HK15109468.7A HK1208861A1 (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
CA2877923A CA2877923C (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
CN201380041191.XA CN104583216A (zh) 2012-06-29 2013-06-26 苯基氨基嘧啶双环化合物及其用途
JP2015178970A JP6153980B2 (ja) 2012-06-29 2015-09-10 フェニルアミノピリミジン二環式化合物およびその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666725P 2012-06-29 2012-06-29
US61/666,725 2012-06-29

Publications (2)

Publication Number Publication Date
AU2013201780A1 AU2013201780A1 (en) 2014-01-16
AU2013201780B2 true AU2013201780B2 (en) 2015-04-02

Family

ID=49778746

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013201780A Ceased AU2013201780B2 (en) 2012-06-29 2013-03-21 Phenyl Amino Pyrimidine Bicyclic Compounds And Uses Thereof

Country Status (11)

Country Link
US (1) US8809359B2 (enExample)
EP (1) EP2867238B1 (enExample)
JP (2) JP5931288B2 (enExample)
CN (1) CN104583216A (enExample)
AU (1) AU2013201780B2 (enExample)
CA (1) CA2877923C (enExample)
ES (1) ES2644606T3 (enExample)
HK (1) HK1208861A1 (enExample)
NZ (1) NZ703343A (enExample)
PT (1) PT2867238T (enExample)
WO (1) WO2014000032A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486941B2 (en) 2007-03-12 2013-07-16 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
TWI729644B (zh) 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
EP3255129B1 (en) * 2016-06-06 2024-01-24 The Lubrizol Corporation Thiol-carboxylic adducts as lubricating additives
CN108707119A (zh) * 2018-06-25 2018-10-26 抚顺大恒化工有限公司 一种Momelotinib的制备方法
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
CN111100076A (zh) * 2019-12-30 2020-05-05 武汉九州钰民医药科技有限公司 Jak抑制剂莫美洛替尼的制备方法
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CN117624189B (zh) * 2023-11-24 2025-11-11 上海馨远医药科技有限公司 一种6-氧杂-3-氮杂双环[3.1.1]庚烷盐酸盐的制备方法
CN117986179A (zh) * 2024-01-16 2024-05-07 深圳市茵诺圣生物科技有限公司 一种顺式-4-羟基-l-脯氨酸的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109943A1 (en) * 2007-03-12 2008-09-18 Cytopia Research Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
WO2009029998A1 (en) * 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481932A (en) 1967-09-01 1969-12-02 Searle & Co 2-anilino-5-methyl-6-phenylpyrimidines and congeners
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
ES2292753T4 (es) 2001-03-29 2009-02-16 Vertex Pharmaceuticals Incorporated Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas.
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
JP2005511502A (ja) 2001-09-12 2005-04-28 ヴィレックス リサーチ インコーポレイテッド 固定化した血小板結合剤を有する血管閉塞固相剤
CA2495386C (en) 2002-08-14 2011-06-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP2172460A1 (en) 2002-11-01 2010-04-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
US7259161B2 (en) 2002-11-04 2007-08-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
US7348335B2 (en) 2002-11-05 2008-03-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
GB0317841D0 (en) 2003-07-30 2003-09-03 Cyclacel Ltd Compound
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
EP1799652A1 (en) 2004-10-13 2007-06-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
US8410173B2 (en) 2006-02-28 2013-04-02 Ym Biosciences Australia Pty Ltd Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
ES2535166T3 (es) 2007-09-04 2015-05-06 The Scripps Research Institute Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas
MX2010005300A (es) * 2007-11-16 2010-06-25 Incyte Corp 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpir imidin-2-aminas como inhibidores de cinasas janus.
HUE030912T2 (en) * 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
RU2011108563A (ru) 2008-08-05 2012-09-10 Таргеджен, Инк. (US) Способы лечения талассемии
JP2013522267A (ja) * 2010-03-17 2013-06-13 エフ．ホフマン−ラ ロシュ アーゲー イミダゾピリジン化合物、組成物、および使用法
WO2012071612A1 (en) 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions
CA2834414A1 (en) 2011-05-02 2012-11-08 Christopher John Burns Multiple myeloma treatment
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109943A1 (en) * 2007-03-12 2008-09-18 Cytopia Research Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
WO2009029998A1 (en) * 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds

Also Published As

Publication number Publication date
EP2867238B1 (en) 2017-08-09
PT2867238T (pt) 2017-10-30
EP2867238A4 (en) 2015-05-06
JP5931288B2 (ja) 2016-06-08
CA2877923A1 (en) 2014-01-03
ES2644606T3 (es) 2017-11-29
JP6153980B2 (ja) 2017-06-28
WO2014000032A1 (en) 2014-01-03
EP2867238A1 (en) 2015-05-06
US20140005161A1 (en) 2014-01-02
AU2013201780A1 (en) 2014-01-16
NZ703343A (en) 2015-12-24
JP2016028076A (ja) 2016-02-25
HK1209120A1 (en) 2016-03-24
CN104583216A (zh) 2015-04-29
JP2015525738A (ja) 2015-09-07
CA2877923C (en) 2017-07-25
US8809359B2 (en) 2014-08-19
HK1208861A1 (en) 2016-03-18

Similar Documents

Publication Publication Date Title
EP2867238B1 (en) Phenyl amino pyrimidine bicyclic compounds and uses thereof
AU2008210266B2 (en) Thiopyrimidine-based compounds and uses thereof
AU2008226327B2 (en) Phenyl amino pyrimidine compounds and uses thereof
EP2215094B1 (en) N-containing heterocyclic compounds
TWI879811B (zh) 作為免疫調節劑之吡啶并[3,2-d]嘧啶化合物
JP2017503834A (ja) 炎症性疾患治療のためのベンゾイミダゾール誘導体及びその医薬組成物
AU2016200866B2 (en) Phenyl amino pyrimidine compounds and uses thereof
HK1209120B (en) Phenyl amino pyrimidine bicyclic compounds and uses thereof
AU2013201306B2 (en) Phenyl Amino Pyrimidine Compounds and Uses Thereof
KR102511209B1 (ko) 벤즈이미다졸 유도체 및 염증 질환의 치료를 위한 그의 약학 조성물
RU2785126C2 (ru) Новые соединения и их фармацевтические композиции для лечения воспалительных заболеваний
TW202313014A (zh) 作為ｐｄ－ｌ１相互作用的免疫調節劑的雜環化合物
AU2013248233A1 (en) N-containing heterocyclic compounds
HK1147252B (en) N-containing heterocyclic compounds
HK1223619A1 (en) Phenylaminopyrimidine compound and use thereof
AU2013263739A1 (en) Thiopyrimidine-based Compounds And Uses Thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired